2025-05-28 - Analysis Report
Okay, here's the report summarizing the provided data for Johnson & Johnson (JNJ), along with analysis and explanations.

## Johnson & Johnson (JNJ) Stock Analysis Report

**Ticker:** JNJ
**Company Overview:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 18.97%
*   **VOO (S&P 500) Cumulative Return:** 83.14%
*   **Absolute Divergence:** -64.16%
*   **Divergence Range (Max: 17.5, Min: -76.4):** Relative Divergence: 13.0

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined.  The relative divergence of 13.0 indicates that JNJ's performance is near the lower end of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha  | Beta  | Cap(B) |
|------------|----------|----------|--------|-------|--------|
| 2015-2017  | 28.0%   | 56.0%   | -1.0%  | 0.0   | 274.9  |
| 2016-2018  | 10.0%   | 10.8%   | -7.0%  | 0.0   | 260.8  |
| 2017-2019  | 20.0%   | 10.8%   | -9.0%  | 0.7   | 303.1  |
| 2018-2020  | 14.0%   | 59.8%   | -12.0% | 0.5   | 335.9  |
| 2019-2021  | 28.0%   | 59.9%   | -26.0% | 0.3   | 374.3  |
| 2020-2022  | 4.0%    | 61.2%   | -2.0%  | 0.3   | 396.7  |
| 2021-2023  | -19.0%  | 61.2%   | -35.0% | 0.4   | 362.6  |
| 2022-2024  | -31.0%  | 61.2%   | -47.0% | 0.3   | 345.2  |
| 2023-2025  | -7.0%   | 69.6%   | -38.0% | 0.2   | 368.7  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has varied significantly, with negative values in recent periods.
*   **MDD:** Maximum Drawdown has been substantial, indicating significant potential for loss during downturns.
*   **Alpha:** Alpha has been consistently negative, suggesting JNJ has underperformed relative to its risk (Beta).
*   **Beta:** Beta values are low, implying that JNJ has been less volatile than the market (S&P 500).

### 2. Recent Price Action

*   **Current Price:** 153.25
*   **Last Market Data:** {'price': 153.25, 'previousClose': 151.64, 'change': 1.06} (Price increased by 1.06)
*   **5-day Moving Average:** 153.13
*   **20-day Moving Average:** 153.37
*   **60-day Moving Average:** 157.39

**Analysis:** The stock price closed higher than the previous close, indicating positive momentum. The price is currently trading slightly below its 20-day moving average and significantly below its 60-day moving average, which might indicate a short-term consolidation phase and potential resistance at the 60-day MA.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 47.32 (Neutral)
*   **PPO:** 0.163
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (4 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** 1.1 (+)
*   **Expected Return:** -205.3%

**Analysis:**

*   **MRI:** The low-risk MRI suggests a relatively stable market environment for JNJ.
*   **RSI:** The RSI is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** The positive PPO suggests that short-term moving averages are above long-term moving averages.
*   **Hybrid Signal:** The hybrid signal recommends caution and suggests a partial buy strategy.
*   **Relative Divergence Change:** The recent increase in relative divergence indicates short-term positive momentum.
*   **Expected Return:** The negative expected return suggests potential underperformance compared to the S&P 500 over a long-term investment horizon.

### 4. Recent News & Significant Events

*   **2025-05-26:** Johnson & Johnson (JNJ) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-05-25:** Analysts are discussing Johnson & Johnson's (JNJ) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-05-27:** Johnson & Johnson (JNJ)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-05-28:** Market experts highlight both risks and opportunities for Johnson & Johnson (JNJ), advising investors to monitor recent news and company announcements.

**Analysis:**  Recent news indicates the stock is experiencing volatility and is subject to both positive and negative factors, including regulatory changes, business developments, and analyst evaluations. Investors should remain vigilant and monitor news and company announcements.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-04-23   | 4.57 | 21.89 B$   |
| 2024-10-23   | 1.12 | 22.47 B$   |
| 2024-07-25   | 1.95 | 22.45 B$   |
| 2024-05-01   | 1.35 | 21.38 B$   |
| 2025-04-23   | 1.35 | 21.38 B$   |

**Analysis:**
*   **EPS:** EPS values have fluctuated across the reported dates, with a notable high in 2025-04-23.
*   **Revenue:** Revenue figures have shown variability, with peaks and troughs over the reported periods.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $78.11B   | 14.08%    |
| 2024-12-31 | $71.49B   | 4.80%     |
| 2024-09-30 | $70.16B   | 3.84%     |
| 2024-06-30 | $71.54B   | 6.55%     |
| 2024-03-31 | $70.02B   | 4.65%     |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, with slight fluctuations quarter-over-quarter.
*   **Profit Margin:** Profit margins have generally been high but have shown a recent decrease.
*   **Equity:** Equity has increased significantly in the most recent quarter.
*   **ROE:** Return on Equity has also increased sharply in the latest quarter, indicating improved profitability relative to equity.

### 7. Overall Summary & Conclusion

Johnson & Johnson (JNJ) has underperformed the S&P 500 significantly, with a large negative divergence. Recent price action shows a slight uptick, but the stock remains below its 60-day moving average. Technical indicators are mixed, with a low MRI but a negative expected return. Recent news suggests potential volatility and significant business developments. Financial data reveals stable revenue but decreasing profit margins, offset by a recent surge in equity and ROE.

**Recommendation:** Given the underperformance compared to the S&P 500, mixed technical signals, and recent volatility, a cautious approach is warranted. Investors should carefully monitor news and company announcements, focusing on factors that could improve the company's long-term growth prospects and profitability. A partial buy strategy, as suggested by the hybrid signal, may be appropriate for investors with a long-term horizon who are willing to accept potential short-term volatility.
